200001167-6

IPOS

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 31 /64

A2

(11) International Publication Number: WO 00/03742

(43) International Publication Date: 27 January 2000 (27.01.00)

(21) International Application Number: PCT/EP99/05571

(22) International Filing Date: 12 July 1999 (12.07.99)

(30) Priority Data:
98401781.4 15 July 1998 (15.07.98) EP

(71) Applicant *(for all designated States except US)*: LIPHA [FR/FR]; 34, rue Saint–Romain, F–69008 Lyon (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BONHOMME, Yves [FR/FR]; Le Buclay, 21, avenue de la Paix, F–69260 Charbonnières les Bains (FR). NICHOLSON, Geoffrey [GB/GB]; 48 Langdon Avenue, Aylesbury, Buckinghamshire HP21 9UT (GB). CAVE, Gillian [GB/GB]; 26 Hilbre Drive, Ellesmere Port CH65 9JQ (GB). NICHOLSON, Sarah, J. [GB/GB]; 4 Redstone Hill, Helsby, Cheshire WA6 9PE (GB).

(74) Agent: OBOLENSKY, Michel; Cabinet Lavoix, 2, place d'Estienne d'Orves, F–75441 Paris Cedex 09 (FR).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: SOLID ORAL DOSAGE FORM COMPRISING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE

(57) Abstract

The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.